# An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

> **NCT05085964** · PHASE2 · TERMINATED · sponsor: **Laboratoires Thea** · enrollment: 21 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Usher Syndrome Type 2

## Interventions

- **DRUG:** RNA antisense oligonucleotide for intravitreal injection

## Key facts

- **NCT ID:** NCT05085964
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-16
- **Primary completion:** 2022-10-18
- **Final completion:** 2022-10-18
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** The sponsor decided to terminate the study early
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05085964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05085964, "An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05085964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*